UNSPSC 51343807: Peginterferon/ribavirin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM800. This VA Drug Class (AM800) classifies this compound as belonging to the group ANTIVIRALS.

UNSPSC 51343807 Peginterferon/ribavirin is a Commodity code under which state and local governments procure pharmaceutical products and medical supplies, though recent opportunities show a mismatch between the code's nominal scope and actual buying activity. The three representative recent solicitations reveal procurement of naloxone and drug deactivation systems (Seminole County, Florida), generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance, covering multiple states including Oregon), and medical and first aid supplies for emergency response (City of Tampa Fire Department). Issuing bodies include county health departments, state health agencies, cities and fire departments, and multi-state cooperative purchasing alliances. The work involves securing pharmaceutical inventory, emergency medical supplies, and OTC products for public health agencies, emergency services, and state employee health plans, with vendors required to navigate wholesaler relationships, supply chain security compliance, manufacturing practice certification, and often state small business enterprise set-asides.

Recent activity concentrates in Florida, Minnesota, Texas, and Oregon. Seminole County posted IFB 60459723LAS in June 2026 for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries, initially a two-year contract with one-year renewal option. The City of Tampa issued ITB 26P00145 in March 2026 for medical and first aid supplies (169 line items for the Fire Department Rescue Division) with an estimated contract value of $700,000 and a sheltered-market small local business enterprise set-aside offering a 5 percent bid discount. MMCAP administered an RFP (S1070000015802, responses due March 26, 2026) for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with contract effectiveness July 1, 2026 and evaluation weighted toward price competitiveness (75 percent). Texas Health and Human Services Commission posted an RFI (HHS0017013, response deadline April 3, 2026) to gather vendor information on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The code shows active state and local pharmaceutical and medical-supply procurement, though the opportunities do not align closely with the code's specific peginterferon/ribavirin antiviral therapy focus.